Results from clinical trials combining VEGF pathway inhibitors and standard anti-tumor cytotoxic drugs indicate that BEVACIZUMAB augments overall survival and/or progression-free survival in patients affected by mesothelioma, non-small cell lung cancer or colon, renal, ovarian or uterine cervical carcinoma (166, 170–174), while RAMUCIRUMAB provides survival benefits in individuals with gastric cancer, non-small cell lung cancer or colon carcinoma (167, 180, 181) (Table 5). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.